Stay Informed About Key Developments for Our Company

The Latest Updates as They Happen

As a valued partner in our shared success, you should be the first to know what’s happening across our company. The articles and announcements below offer a comprehensive glimpse into the recent developments that shape our business and growth strategies.

 

News
81 - 90of about 315 News
81 - 90of about 315 News
May 21, 2021
Not intended for U.S. and UK Media
Positive CHMP opinion for Bayer’s new symptomatic chronic heart failure treatment vericiguat
READ MORE
May 19, 2021
Not intended for U.S. and UK Media - ASCO Annual Meeting 2021:
Long-term data on Vitrakvi™ (larotrectinib) confirm sustained clinical benefit of greater than four years in patients with TRK fusion cancer regardless of tumor type and age
READ MORE
May 17, 2021
Not intended for U.S. and UK Media - Late-Breaking Data from exploratory analysis of Phase III FIDELIO-DKD study presented at the American College of Cardiology’s (ACC) 70th Annual Scientific Session (ACC.21)
Finerenone has potential to reduce the risk of new onset atrial fibrillation or flutter in patients with chronic kidney disease and type 2 diabetes
READ MORE
May 12, 2021
First quarter of 2021:
Bayer: successful start to 2021
READ MORE
May 11, 2021
Not intended for U.S. and UK Media
Bayer presents expanded research and new approaches to advance cancer care at 2021 ASCO Annual Meeting
READ MORE
May 10, 2021
Not intended for U.S. and UK Media
Bayer’s finerenone meets primary endpoint in Phase III FIGARO-DKD cardiovascular outcomes study in patients with chronic kidney disease and type 2 diabetes
READ MORE
April 27, 2021
CEO Werner Baumann at the Annual Stockholders’ Meeting of Bayer AG:
"We’re optimistic for the future"
READ MORE
April 10, 2021
Not intended for U.S. and UK Media - Plenary Session at AACR Annual Meeting 2021:
Combination of copanlisib and rituximab significantly increases progression-free survival in patients with relapsed indolent non-Hodgkin's Lymphoma
READ MORE
April 06, 2021
Not intended for U.S. and UK Media
Bayer to present new clinical data in indolent non-Hodgkin’s Lymphoma and additional research on its oncology portfolio at AACR Annual Meeting 2021
READ MORE
March 23, 2021
Not intended for U.S. and UK Media
Bayer receives approval for Vitrakvi™ in Japan
READ MORE
81 - 90of about 315 News
81 - 90of about 315 News

 

Subscribe To Our Investor News Email Alerts

Ad-Hoc Releases
Discover Bayer's Latest Ad-Hoc Releases
read more